Objective: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment- resistant major depressive disorder (TRD) patients in real practice. Methods: Nine patients were prescribed Neuropharmagen? for selection of antidepressants for individual patient and their clinical outcomes were followed. Results: After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients. Conclusion: Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients.
Lee K.H., Bahk W.-M., Lee S.-J., Serretti A., Pae C.-U. (2021). A practical utility and benefit of pharmacogenetic-based antidepressant treatment strategy for major depressive disorder patients with difficult-to-treat. CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 19(1), 160-165 [10.9758/CPN.2021.19.1.160].
A practical utility and benefit of pharmacogenetic-based antidepressant treatment strategy for major depressive disorder patients with difficult-to-treat
Serretti A.;
2021
Abstract
Objective: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment- resistant major depressive disorder (TRD) patients in real practice. Methods: Nine patients were prescribed Neuropharmagen? for selection of antidepressants for individual patient and their clinical outcomes were followed. Results: After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients. Conclusion: Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients.File | Dimensione | Formato | |
---|---|---|---|
cpn019-01-17.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione
235.13 kB
Formato
Adobe PDF
|
235.13 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.